Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 single-arm study of Adcetris in relapsed or refractory systemic anaplastic large cell lymphoma
2012-004128-39Phase 4Unknown
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Apr 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brentuximab vedotin in systemic anaplastic large cell lymphoma (ALCL) and anaplastic large cell lymphoma (ALCL), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Objective response rate per independent review facility. Status: unknown.
02
Drugs
brentuximab vedotin
03
Conditions
systemic anaplastic large cell lymphoma (ALCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2012-004128-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004128-39.